Pharmaceutical Industry Pipeline Increased By 5% in Q1 2016

PUNE, India, August 9, 2016 /PRNewswire/ --

A new industry report titled "Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline" benchmarks pipeline against its size across each segment in 2015, covering an assessment of the level of first-in-class innovation. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

The top three therapy areas - namely oncology, infectious diseases and central nervous system (CNS) disorders - accounted for a combined 68% of the overall pharmaceutical industry pipeline as of Q1 2016. Oncology is by far the largest therapy area, with almost 7,000 products in active development, almost matching the combined size of the next two therapy areas, infectious diseases and CNS disorders, which each have over 3,000 products in active development. There is also a great deal of pharmaceuticals pipeline activity in the next few therapy areas, with immunology, metabolic disorders and cardiovascular diseases each having pipelines consisting of over 1,000 products. Complete report on pharmaceutical pipeline and its innovation for 2016 is spread across 70 pages and now available at http://www.rnrmarketresearch.com/innovation-tracking-factbook-2016-an-assessment-of-the-pharmaceutical-pipeline-market-report.html .

With the cost of bringing a single novel drug to market estimated to be $2.6 billion in 2015, pharmaceutical companies are increasingly looking towards developing first-in-class treatments to maximize revenue and stay ahead of competition. Higher-risk programs for innovative first-in-class products remain attractive and have led to some of the most clinically and commercially successful products over the past decade, and the 4,964 first-in-class products currently in development represent 37.9% of pharmaceutical pipeline products with a disclosed molecular target.

Overall, 'me-too' drugs, which are structurally very similar to already-established drugs, have traditionally been highly commercially and clinically successful. These products continue to provide a well-established pathway for promising product developments due to a lower risk profile based on safer and more cost-effective incremental innovation. Oncology is a rapidly growing therapy area, in terms of both me-too and first-in-class oncology products. This growth was generally substantial in Q1 2016, with the largest three indications in terms of the number of products - namely breast, lung and colorectal cancer - each exhibiting pipeline growth in excess of 15%. The most rapid growth was witnessed in the smallest therapy areas, led by women's health, which grew by 55% in Q1 2016.

Pharmaceuticals industry deals analysis covering licensing deals, co-development deals, mergers and acquisitions as well as capital raising are discussed in this market research report titled Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=635387 .

On a related note, the Global Oncology Partnering 2010-2016: Deal trends, players and financials market research report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. a comprehensive appendix is provided with each report of all Oncology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Oncology partnering and dealmaking since 2010. This report contains a comprehensive listing of all oncology partnering deals announced since 2010 including financial terms, where available, including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted t- the Securities Exchange Commission by companies and their partners. In conclusion, this report provides everything a prospective dealmaker needs t- know about partnering in the research, development and commercialization of Oncology technologies and products. Read more at http://www.rnrmarketresearch.com/global-oncology-partnering-2010-2015-deal-trends-players-and-financials-market-report.html .

Explore more reports on pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed